Form 4: CytoDyn CEO Jacob Lalezari Granted 3 Million Stock Options
SEC Form 4 Filing
CytoDyn's CEO, Jacob Lalezari, was granted 3,000,000 non-qualified stock options on March 7, 2024, vesting monthly over four years.
Summary
- Jacob P. Lalezari, CEO of CytoDyn Inc., was granted 3,000,000 non-qualified stock options on March 7, 2024.
- The exercise price of these options is $0.21 per share.
- The options vest in 48 monthly installments starting April 7, 2024, and ending March 7, 2028, contingent upon continuous service.
- The options expire on March 7, 2034.
- Lalezari also has a power of attorney agreement effective February 13, 2024, allowing Mitchell Cohen, Tyler Blok, and/or Nathan Fox to file SEC forms on his behalf.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and can be seen as a positive sign of aligning management's interests with shareholders. However, it's not a major event that would drastically alter the company's outlook.
Positives
- The granting of stock options to the CEO can align his interests with those of the shareholders, incentivizing him to increase the company's value.
Risks
- The vesting schedule is dependent on continuous service, so any departure of the CEO could impact the full realization of these options.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's performance, but the vesting schedule of the stock options suggests a long-term commitment from the CEO.
Industry Context
Granting stock options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders. The specific terms of the options, such as the vesting schedule and exercise price, are tailored to the company's specific circumstances and goals.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their leadership teams.
- The vesting schedule of 48 months is fairly typical, aligning with industry norms for long-term performance incentives.
- The exercise price is dependent on the current market price of the stock.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to improve company performance.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| February 13, 2024 | Effective date of the Limited Power of Attorney. |
| March 7, 2024 | Date of the stock option grant. |
| April 7, 2024 | Start date of the monthly vesting installments. |
| March 7, 2028 | End date of the monthly vesting installments. |
| March 7, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.